15. Large Granular Lymphocyte Leukemia

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Xin Liu and
  2. Thomas P. Loughran Jr.

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch15

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Liu, X. and Loughran, T. P. (2011) Large Granular Lymphocyte Leukemia, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch15

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Penn State Hershey Cancer Institute, Penn State University, Hershey, Pennsylvania, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016

SEARCH

Keywords:

  • Large granular lymphocyte leukemia;
  • review

Summary

Large granular lymphocyte (LGL) leukemia is a rare lymphoproliferative malignancy that arises from either CD3+ mature cytotoxic T-cell or CD3 natural killer (NK)-cell lineage. It is a heterogeneous disorder due to distinct morphological, immunophenotypical, and clinical features among patients, which distinguish indolent from aggressive subtypes of LGL leukemia and guide the selection of therapies. Patients with indolent T-cell or NK-cell LGL leukemia are usually treated with immunosuppressive therapies, while aggressive T-cell or NK-cell LGL leukemia requires intensive chemotherapy. Novel targeted therapeutics, using either small molecules (such as tipifarib) or monoclonal antibodies (including anti-CD2 and CD52), are currently being tested in clinical trials.